Many people suffer from hyperpigmentation, often known as skin pigmentation. It is one of the most common causes of face wrinkles and dark under-eye circles. This might be due to hereditary causes, skin damage, hormone imbalance, excessive sun exposure, medicine, or even a bad diet. There are several reasons of this skin pigmentation issue. It is critical to select the appropriate treatment approach to eliminate dermal hyperpigmentation.
Many studies have been published on the effectiveness of hyperpigmentation treatment devices. The International Society of Dermatology (ISD) conducted a research that included 740 participants with skin pigmentation issues. These individuals were invited to fill out an online questionnaire regarding their skin issues and the causes behind their worries. Participants were also asked to assess the efficacy of various cosmetic treatments. An intriguing discovery was that nearly half of the individuals suggested intrusive techniques to cure their skin concerns.
According to the report, the use of non-invasive techniques has grown in popularity in recent years. Patients are more ready to explore novel treatments, such as non-ablative laser and microdermabrasion, as a result of this. Patients can get rid of various skin-related issues using non-ablative treatments, such as acne, wrinkles, dark eye circles, sun spots, and so on. Non-ablative and non-microdermabrasion treatments have been demonstrated in studies to be extremely successful in treating most forms of hyperpigmentation issues.
However, there is one type of hyperpigmentation condition that cannot be addressed with any of the currently available hyperpigmentation therapy devices. Melasma, often known as moleskin, is a skin condition. It is a type of skin pigmentation issue in which a person's skin becomes darker than normal. Melasma is caused by the body's failure to generate an appropriate quantity of melanin, the pigment that gives skin color. The plasma begins to develop in dark patches on the skin over time, causing unattractive skin discoloration and uneven pigmentation.
There are two treatments that can be performed to treat hyperpigmentation induced by melanism. The first is a bleaching treatment, and the second is phototherapy, also known as photodynamic therapy. Bleaching is a technique for eliminating hyperpigmented areas that involves the use of specific chemical or polishing chemicals that remove the top layer of the skin, leaving behind lighter patches of skin. Within a few months, the patches generally fade or vanish. However, even after completing this therapy, additional spots may emerge in certain situations.
Photo-dynamic treatment is a distinct method that is frequently used to treat melanoma-related hyperpigmentation. It entails the employment of a laser to deliver regulated light to the afflicted areas. This method is thought to be more successful than bleaching. Because lasers are utilized to deliver focused light to the afflicted regions, there is less chance of secondary infections and therefore a lower risk of adverse effects. There are currently a plethora of firms on the market who provide laser equipment for photodynamic treatment. This is likely to drive up demand for this hyperpigmentation therapy device in the coming years, given the present issues that patients with melisma face.
Over the last two decades, there has been an increase in the demand for hyperpigmentation treatment devices. The number of persons impacted by this illness has been gradually growing as well. As a result, numerous firms have released a number of items aimed at providing a remedy to this disease.
Hyperpigmentation Disorders Treatment Market: Information by Treatment Type (Topical Drugs, Chemical Peels, and Laser Therapy), by Disease Indication (Melasma, Solar and Lentigines), by End-User (Hospitals and Others) — Global Forecast till 2023The Hyperpigmentation Disorders Treatment Market report offers insights into the leading market players and presents an assessment of their current market position.
Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M activities, and the latest R initiatives is also available in the reportMajor Key PlayersThe key strategies followed by the players operating in the global Hyperpigmentation Disorders Treatment Market were innovation, product development, acquisition, and expansion.Allergan, Inc., Bayer AG, EpiPharm AG, Episciences, Inc., Galderma laboratories (Nestle Skin Health S.A), Obagi Cosmeceuticals LLC, Pierre Fabre, RXi Pharmaceuticals Corporation, SkinCeuticals International, and Vivier Pharma.
Market Segment AnalysisGlobal Hyperpigmentation Disorders Treatment Market, by Treatment TypeTopical DrugsChemical PeelsMicrodermabrasionLaser TherapyPhototherapyOthersGlobal Hyperpigmentation Disorders Treatment Market, by Disease IndicationMelasmaSolar LentiginesPost-inflammatory HyperpigmentationSynchrocyclotronsOthersGlobal Hyperpigmentation Disorders Treatment Market, by End-UserHospitalsAesthetic Clinics & Dermatology CentersOthers Top of FormKey Study Highlights:This report for Hyperpigmentation Disorders Treatment Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance.The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market.
The report also gives a broad study of the different market segments and regions.Regional AnalysisGeographically, the global Hyperpigmentation Disorders Treatment Market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.Browse Full Report Page Enabled with complete Table of Content at https://www.marketresearchfuture.com/reports/hyperpigmentation-disorders-treatment-market-7462Chapter 9.
Global Hyperpigmentation Disorders Treatment Market By Region9.1 Introduction9.2 America9.2.1 North America9.2.1.1 U.S.9.2.1.2 Canada9.2.2 South America9.3 Europe9.3.1 Western Europe9.3.1.1 Germany9.3.1.2 France9.3.1.3 Italy9.3.1.4 Spain9.3.1.5 U.K.9.3.1.6 Rest Of Western Europe9.3.2 Eastern Europe9.4 Asia Pacific9.4.1 Japan9.4.2 China9.4.3 India9.4.4 Australia9.4.5 Republic Of Korea9.4.6 Rest Of Asia Pacific9.5 The Middle East & Africa9.5.1 United Arab Emirates9.5.2 Saudi Arabia9.5.3 Oman9.5.4 Kuwait9.5.5 Qatar9.5.6 Rest Of The Middle East & AfricaAbout Market Research Future: MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.Contact:+1 646 845 9312 | Email: [email protected]
Transparency Market Research (TMR) has published a new report titled ‘Hyperpigmentation Disorders Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the report, the global hyperpigmentation disorders treatment market was valued at US$ 3,947.3 Mn in 2017 and is projected to reach US$ 7,225.6 Mn by 2026, expanding at a CAGR of 7.2% during the forecast period from 2018 to 2026.
The report suggests that augmented adoption of lasers in hyperpigmentation disorders treatment, decrease in social taboos boosting acceptance of pigmentation disorders treatment measures, increase in prevalence of pigmentation related disorders, rise in awareness about skin rejuvenation, improving lifestyle, and increasing disposable income are likely to drive the hyperpigmentation disorders treatment market from 2018 to 2026.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=46644Despite its considerable patient population globally, the hyperpigmentation disorders treatment market has often been overlooked and has remained stagnant for the past few decades, with no novel drugs entering the arena.
The lack of dedicated research programs has been attributed to pharmaceutical companies viewing topicals, the mainstay of hyperpigmentation disorders treatment therapy, as being inexpensive with a poor return on investment.
Instead, the market has shifted towards reformulations of existing products and/or fixed-dose combination therapies.
Examples of the latter include combination products by key dermatology players, such as Galderma’s Tri-Luma (fluocinolone acetonide/hydroquinone/tretinoin).TOC of Report – https://www.transparencymarketresearch.com/report-toc/46644 Innovative products in hyperpigmentation disorders should focus on cost-effectiveness, potential to improve compliance.
Historically, pharmaceutical companies have been reluctant to enter the hyperpigmentation disorders market due to the poor return on investment in this competitive landscape.
